AIxCrypto Pivots to Crypto Treasury, Secures $41M Private Placement

TL;DR

**AIXC is ditching biotech for bitcoin, a high-stakes gamble that could either skyrocket or crash and burn.**

AI Summary

AIxCrypto Holdings, Inc. (AIXC) is undergoing a significant strategic pivot, transitioning from an early-clinical-stage therapeutics company to one focused on cryptocurrency treasury operations and AI integration, while retaining a reduced therapeutics pipeline. On September 19, 2025, the company secured a $41,000,000 private placement offering, with proceeds earmarked for existing debt repayment, funding current business operations, and establishing its cryptocurrency treasury. The new C10 Treasury strategy involves an 80% passive allocation tracking the top 10 cryptocurrencies by market capitalization and a 20% active allocation based on quantitative analysis, with plans to include hedging strategies. This shift follows the sale of its Qualigen, Inc. diagnostics subsidiary for $5.4 million in cash on July 20, 2023, and a subsequent $100,000 loss from discontinued operations in Q2 2024 due to an early escrow settlement. AIXC also reduced its ownership in NanoSynex from 52.8% to 39.90% by November 22, 2023, by surrendering Series B Preferred Shares and promissory notes totaling approximately $3.0 million, eliminating future funding obligations. The company's common stock underwent a 1-for-50 reverse stock split on November 5, 2024, and its ticker symbol changed to 'AIXC' on November 20, 2025, reflecting its new strategic direction.

Why It Matters

This S-1 filing signals a dramatic strategic shift for AIxCrypto Holdings, Inc., moving away from its core therapeutics business towards a speculative cryptocurrency treasury model. For investors, this represents a high-risk, high-reward proposition, as the company's valuation will now be heavily tied to volatile crypto markets rather than clinical trial outcomes. Employees in the therapeutics division may face uncertainty, while new hires in crypto management will be critical. Competitively, AIXC is entering a crowded and rapidly evolving crypto investment space, differentiating itself from traditional biotech peers and potentially competing with specialized crypto funds. The broader market will watch to see if this pivot can generate sustainable value, given the inherent volatility and regulatory ambiguities of the cryptocurrency sector.

Risk Assessment

Risk Level: high — The company is undergoing a significant business model transformation, pivoting from a therapeutics company to one focused on cryptocurrency treasury operations, which inherently carries high market volatility and regulatory risks. The S-1 highlights the need for 'Stockholder Approval' for the conversion of Series B Preferred Stock exceeding 19.99% of outstanding shares, indicating potential dilution and governance challenges. Furthermore, the company's prior history includes a 1-for-50 reverse stock split on November 5, 2024, often a red flag for struggling companies, and a $100,000 loss from discontinued operations in Q2 2024, suggesting past operational difficulties.

Analyst Insight

Investors should approach AIXC with extreme caution, recognizing the speculative nature of its new cryptocurrency-focused business model. Conduct thorough due diligence on the management team's crypto expertise and the specifics of their 'Quantitatively Driven module.' Consider this a high-risk, potentially high-reward play, suitable only for investors with a strong appetite for volatility and a deep understanding of the cryptocurrency market.

Key Numbers

• $41,000,000 — Private Placement Offering (Cash raised by AIxCrypto Holdings, Inc. on September 19, 2025, for debt, operations, and crypto treasury.)
• 18,121,496 — Shares of Common Stock (Maximum shares registered for resale by Selling Stockholders, including 17,784,064 from Series B conversion.)
• $2.246 — Conversion Price (Price per share for Series B Convertible Preferred Stock conversion into common stock.)
• $2.35 — Last Reported Sales Price (AIXC common stock price on Nasdaq Capital Market as of December 1, 2025.)
• 1-for-50 — Reverse Stock Split Ratio (Implemented on November 5, 2024, to adjust outstanding common stock.)
• $5.4 million — Net Purchase Price (Cash received from the sale of Qualigen, Inc. subsidiary on July 20, 2023.)
• $100,000 — Loss from Discontinued Operations (Incurred in Q2 2024 due to early settlement of Qualigen, Inc. escrow account.)
• 39.90% — Ownership in NanoSynex (Reduced ownership percentage as of November 22, 2023, from an initial 52.8%.)
• $1,750,000 — Total Funding Payment (Maximum investment committed to Marizyme, Inc. for DuraGraft™ commercialization.)
• 19.99% — Exchange Cap (Maximum ownership of Common Stock for any purchaser without stockholder approval, per Nasdaq Listing Rule 5635(d).)

Key Players & Entities

• AIxCrypto Holdings, Inc. (company) — Registrant and issuer of securities
• Kevin A. Richardson II (person) — Co-Chief Executive Officer of AIxCrypto Holdings, Inc.
• Jiawei Wang (person) — Co-Chief Executive Officer of AIxCrypto Holdings, Inc.
• Joseph Lucosky, Esq. (person) — Legal counsel from Lucosky Brookman LLP
• Peter Campitiello, Esq. (person) — Legal counsel from Lucosky Brookman LLP
• Faraday Future Intelligent Electric Inc. (company) — Lead Investor in the $41,000,000 private placement
• Marizyme, Inc. (company) — Co-Development Agreement partner for DuraGraft™
• NanoSynex, Ltd. (company) — Privately-held microbiologics diagnostic company in which AIXC holds a minority interest
• Chembio Diagnostics, Inc. (company) — Purchaser of Qualigen, Inc. subsidiary
• U.S. Securities and Exchange Commission (regulator) — Regulatory body overseeing the S-1 filing

FAQ

Key Financial Figures

• $0.001 — 6 shares of our common stock, par value $0.001 per share, including 337,432 shares of
• $1,000 — eries B Preferred has a stated value of $1,000 and is convertible into a number of sha
• $2.246 — alue divided by the conversion price of $2.246 per share of Series B Preferred. Under
• $800,000 — ed that we would invest an aggregate of $800,000 in Marizyme in April 2024 (the “F
• $200,000 — ding Payment”) and pay Marizyme a $200,000 Exclusivity Fee (Provided, that if the
• $1,500,000 — d from time to time to up to a total of $1,500,000.) To date our Funding Payment investmen
• $500,000 — our Funding Payment investment has been $500,000, and in July 2024 we have advanced an a
• $1,250,000 — uly 2024 we have advanced an additional $1,250,000 pursuant to an 18% demand promissory no
• $1,750,000 — tal Funding Payment to up to a total of $1,750,000. In October 2025, we advanced an additi
• $100,000 — October 2025, we advanced an additional $100,000 to Marizyme and increased the amount of
• $5.4 million — t purchase price for Qualigen, Inc. was $5.4 million in cash, of which $450,000 was being he
• $450,000 — Inc. was $5.4 million in cash, of which $450,000 was being held in escrow to satisfy cer
• $350,000 — . In exchange for the early settlement, $350,000 was paid to the Company, and $100,000 w
• $560,000 — xcept for obligations to lend NanoSynex $560,000 on or before November 30, 2023, and $67
• $670,000 — 000 on or before November 30, 2023, and $670,000 on or before March 31, 2024), surrender

Filing Documents

• forms-1.htm (S-1) — 621KB
• ex5-1.htm (EX-5.1) — 11KB
• ex23-1.htm (EX-23.1) — 4KB
• ex23-2.htm (EX-23.2) — 4KB
• ex107.htm (EX-FILING FEES) — 26KB
• forms-1_001.jpg (GRAPHIC) — 8KB
• ex5-1_001.jpg (GRAPHIC) — 46KB
• ex5-1_002.jpg (GRAPHIC) — 8KB
• 0001493152-25-026046.txt ( ) — 874KB
• ex107_htm.xml (XML) — 6KB

USE OF PROCEEDS

USE OF PROCEEDS 29 SELLING STOCKHOLDERS 29 PLAN OF DISTRIBUTION 31 LEGAL MATTERS 33 EXPERTS 33 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 33 WHERE YOU CAN FIND MORE INFORMATION 34 3 ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 that we filed with the Securities and Exchange Commission (the “SEC”). The registration statement relates to the resale, from time to time, of shares of our common stock by the selling stockholders named in this prospectus (the “Selling Stockholders”) or their pledgees, donees, transferees, or other successors-in-interest. We will not receive any of the proceeds from the sale of the shares by the Selling Stockholders. This prospectus provides you with a general description of the shares of common stock that may be offered for resale by the Selling Stockholders. You should rely only on the information contained in this prospectus, any applicable prospectus supplement, and the documents incorporated by reference. If the information in a prospectus supplement is inconsistent with the information contained in this prospectus, you should rely on the prospectus supplement. Neither we nor the Selling Stockholders have authorized any other person to provide you with different information, and neither we nor the Selling Stockholders take any responsibility for, nor can we provide assurance as to the reliability of, information that others may provide. You should not assume that the information in this prospectus, any applicable prospectus supplement, or any incorporated document is accurate as of any date other than its date. Our business, financial condition, results of operations, and prospects may have changed since those dates. We may file a prospectus supplement or a post-effective amendment to the registration statement to add, update, or change information contained in this prospectus. You should read this prospectus, together with any prospectus

forward-looking statements include, but are not limited to, statements regarding

forward-looking statements include, but are not limited to, statements regarding: our ability to obtain sufficient capital to fund operations and development activities; our ability to successfully develop, test, and commercialize product candidates; the progress, timing, and outcomes of preclinical studies and clinical trials; our ability to obtain regulatory approvals and complete clinical trials on expected timelines; the protection and enforceability of our intellectual property rights; and our ability to compete effectively in our industry. Forward-looking from those anticipated due to a variety of factors. You should not place undue reliance on these statements, which speak only as of the date of this prospectus (or as of the date of the documents incorporated by reference). We disclaim any obligation to update such statements except as required by law. For a discussion of factors that could cause actual results to differ materially from those expressed or implied by forward-looking statements, see the section titled “Risk Factors” in this prospectus and in the sections titled “Business,” “Risk Factors,” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and in other documents we file with the SEC that are incorporated by reference into this prospectus. 5 PROSPECTUS SUMMARY This summary highlights information contained elsewhere in, or incorporated by reference into, this prospectus. It does not contain all of the information that you should consider before making an investment decision. You should read this entire prospectus, including the documents incorporated by reference, carefully before investing in our securities. In part

View Full Filing

View this S-1 filing on SEC EDGAR